PMID- 19796969
OWN - NLM
STAT- MEDLINE
DCOM- 20101228
LR  - 20151119
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 24
IP  - 5
DP  - 2010 Sep-Oct
TI  - Transforming growth factor beta 1 as a biomarker of diabetic peripheral 
      neuropathy: cross-sectional study.
PG  - 306-12
LID - 10.1016/j.jdiacomp.2009.07.007 [doi]
AB  - BACKGROUND: Simple and efficient screening methods are lacking for diabetic 
      peripheral neuropathy (DPN), the most common and most difficult to treat of the 
      long-term diabetic complications. Increased levels of transforming growth factor 
      beta 1 (TGFbeta1) in type 2 diabetic patients (T2DM) plays an immunomodulatory 
      role in diabetic nephropathy and, possibly, in atherosclerotic evolution. Since 
      preliminary interrelationships between experimental DPN and TGFbeta1 have been 
      observed, we sought to assess whether TGFbeta1 could be a biomarker molecule for 
      human DPN. MATERIALS AND METHODS: Cross-sectional cohort study focused on the 
      assessment of the interrelationships between TGFbeta1 levels, cardiovascular 
      disease (CVD), diabetic nephropathy (DNF), and neuropathy (DPN) in a group of 
      T2DM patients (N=180; male 117, female 63) randomly selected from the North 
      Catalonia Diabetes Study. DPN was diagnosed using clinical and neurophysiology 
      evaluation. Incipient DNF was assessed by microalbuminuria (MAU). Total TGFbeta1 
      (without acidification) was measured by immunoassay by ELISA (Promega). RESULTS: 
      DPN correlated with age, time of diabetes duration, MAU, CVD, and TGFbeta1 
      (P<.0001). Log-transformed TGFbeta1 (logTGbeta1) was significantly higher in 
      patients with DPN than in those without (P<.0005). LogTGFbeta1 (OR=7.5; P=.006), 
      age (OR=1.1; P<.0005), and logMAU (OR=2.0; P=.016) appear as significant 
      estimators of the occurrence of DPN in our series. The integrated ROC curve 
      evaluation with these three parameters expressed an important sensitivity 
      (78.1%), specificity (76.0%), positive predictive value (79.2%), and negative 
      predictive value (70.3%) in relation to DPN presence. DISCUSSION: TGFbeta1 stands 
      as an important biomarker molecule for DFN and DPN screening in our series. 
      Further prospective studies are warranted.
FAU - Ybarra, Juan
AU  - Ybarra J
AD  - Instituto de Cardiologia Avanzada (ICAMED), Centro Medico Teknon, Barcelona, 
      Spain. juanybarra@hotmail.com
FAU - Pou, Josep M
AU  - Pou JM
FAU - Romeo, June Hart
AU  - Romeo JH
FAU - Merce, Javier
AU  - Merce J
FAU - Jurado, Jeroni
AU  - Jurado J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090930
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Biomarkers)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/blood
MH  - Cohort Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/*complications
MH  - Diabetic Nephropathies/*blood
MH  - Diabetic Neuropathies/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Transforming Growth Factor beta1/*blood
EDAT- 2009/10/03 06:00
MHDA- 2010/12/29 06:00
CRDT- 2009/10/03 06:00
PHST- 2009/04/06 00:00 [received]
PHST- 2009/07/06 00:00 [revised]
PHST- 2009/07/31 00:00 [accepted]
PHST- 2009/10/03 06:00 [entrez]
PHST- 2009/10/03 06:00 [pubmed]
PHST- 2010/12/29 06:00 [medline]
AID - S1056-8727(09)00091-9 [pii]
AID - 10.1016/j.jdiacomp.2009.07.007 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2010 Sep-Oct;24(5):306-12. doi: 
      10.1016/j.jdiacomp.2009.07.007. Epub 2009 Sep 30.